WHO WE ARE
CELZ has developed/acquired a robust intellectual property (IP) portfolio related to the utilization of stem cells to improve patient lives in the areas of immunology, urology, neurology, and orthopedics.
This IP portfolio positions us at the forefront of the regenerative medicine industry (set to grow to $79Bn 2026). We plan to commercialize these products on our own and in collaboration with strategic partners.
Chief Executive Officer
Chief Financial Officer
Director of Clinical Development
Bruce S. Urdang
We work with Not For Profit and For Profit Organizations in the further development of our technologies. As related to Translational Projects we have defined policies and protocols in place that allows for indirect costs up to 25 percent of the direct costs. Direct costs + 25% of direct costs = Total project budget.
For inquiries, please contact the company: TimW@CreativeMedicalTechnology.com